Treasury poised to tighten scrutiny on Chinese biotech acquisitions
The U.S. Treasury Department is expected to implement stricter rules governing Chinese biotechnology transactions, signaling a shift toward more rigorous oversight of cross-border pharmaceutical deals. This development follows months of industry efforts to avoid harsh regulatory treatment and comes amid heightened geopolitical tensions. While previous drafts suggested a distinction between standard licensing and sensitive technologies, the new framework is anticipated to impose tighter constraints on acquisitions and partnerships involving Chinese firms.
Key points
- Treasury Secretary Scott Bessent is expected to enforce a more stringent assessment of Chinese biotech deals under new regulatory rules.
- The pharmaceutical industry has been bracing for this stricter approach despite previous months of work to escape harsh restrictions.
- The new rules are part of a broader regulatory environment that distinguishes biopharma from other sectors like AI and semiconductors, though scrutiny remains high.
- This regulatory shift occurs after a record-breaking first half of 2026 for Chinese out-licensing deals, which reached $110 billion in value.
Background
Recent months have seen significant activity in cross-border biotech transactions, including major deals such as Roche's $1.16 billion agreement with Rona Therapeutics and Novartis's $7.8 billion acquisition of rights to Abogen Biosciences' mRNA therapy. In September 2026, the Treasury drafted rules intended to preserve most drug licensing deals while excluding those linked to weaponizable biotech. Additionally, China released draft export rules in October 2026 to restrict foreign acquisitions of core biotech platforms, specifically targeting cell and gene therapy technologies. These developments highlight the complex interplay between U.S. regulatory efforts and Chinese protective measures in the biopharmaceutical sector.
Why it matters
The anticipated stricter Treasury rules could significantly impact the flow of capital and technology between U.S. and Chinese biotech firms. As the industry braces for a more stringent assessment, companies may face increased compliance costs and delays in closing deals. This regulatory tightening reflects broader geopolitical tensions and could influence the future landscape of global pharmaceutical innovation and collaboration.
What to watch
The Treasury Department is expected to finalize and announce the new rules in the coming weeks. Industry stakeholders will closely monitor the specific criteria for deal approval and the extent of the restrictions. Companies may need to adjust their strategies for cross-border partnerships and acquisitions to comply with the new regulatory framework.
Want the full story? Read the original reporting
Read on Endpoints News